206 related articles for article (PubMed ID: 19773449)
1. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.
Holcomb IN; Young JM; Coleman IM; Salari K; Grove DI; Hsu L; True LD; Roudier MP; Morrissey CM; Higano CS; Nelson PS; Vessella RL; Trask BJ
Cancer Res; 2009 Oct; 69(19):7793-802. PubMed ID: 19773449
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cher ML; Bova GS; Moore DH; Small EJ; Carroll PR; Pin SS; Epstein JI; Isaacs WB; Jensen RH
Cancer Res; 1996 Jul; 56(13):3091-102. PubMed ID: 8674067
[TBL] [Abstract][Full Text] [Related]
3. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
[TBL] [Abstract][Full Text] [Related]
4. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.
Cher ML; MacGrogan D; Bookstein R; Brown JA; Jenkins RB; Jensen RH
Genes Chromosomes Cancer; 1994 Nov; 11(3):153-62. PubMed ID: 7530484
[TBL] [Abstract][Full Text] [Related]
5. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
6. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
7. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.
Holcomb IN; Grove DI; Kinnunen M; Friedman CL; Gallaher IS; Morgan TM; Sather CL; Delrow JJ; Nelson PS; Lange PH; Ellis WJ; True LD; Young JM; Hsu L; Trask BJ; Vessella RL
Cancer Res; 2008 Jul; 68(14):5599-608. PubMed ID: 18632612
[TBL] [Abstract][Full Text] [Related]
8. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
Lapointe J; Li C; Giacomini CP; Salari K; Huang S; Wang P; Ferrari M; Hernandez-Boussard T; Brooks JD; Pollack JR
Cancer Res; 2007 Sep; 67(18):8504-10. PubMed ID: 17875689
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
[TBL] [Abstract][Full Text] [Related]
11. Integrative genomic profiling of human prostate cancer.
Taylor BS; Schultz N; Hieronymus H; Gopalan A; Xiao Y; Carver BS; Arora VK; Kaushik P; Cerami E; Reva B; Antipin Y; Mitsiades N; Landers T; Dolgalev I; Major JE; Wilson M; Socci ND; Lash AE; Heguy A; Eastham JA; Scher HI; Reuter VE; Scardino PT; Sander C; Sawyers CL; Gerald WL
Cancer Cell; 2010 Jul; 18(1):11-22. PubMed ID: 20579941
[TBL] [Abstract][Full Text] [Related]
12. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
13. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
Smit FP; Salagierski M; Jannink S; Schalken JA
BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
[TBL] [Abstract][Full Text] [Related]
14. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
17. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
[TBL] [Abstract][Full Text] [Related]
18. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
[TBL] [Abstract][Full Text] [Related]
19. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
[TBL] [Abstract][Full Text] [Related]
20. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
FitzGerald LM; Agalliu I; Johnson K; Miller MA; Kwon EM; Hurtado-Coll A; Fazli L; Rajput AB; Gleave ME; Cox ME; Ostrander EA; Stanford JL; Huntsman DG
BMC Cancer; 2008 Aug; 8():230. PubMed ID: 18694509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
